Skip to main content
. 2015 Dec 24;7(4):3847–3856. doi: 10.18632/oncotarget.6758

Figure 5. Effect of high dose-AZD9291 treatment after acquisition of EGFR-TKI resistance.

Figure 5

(A) After acquisition of resistance to treatment with 25 mg/kg of erlotinib (N = 5) or 6 mg/kg of AZD9291 (N = 5), the mice were given daily oral treatment with AZD9291 (25 mg/kg) for 8 days. The representative images are shown. (B) Cancer cells from the leptomeningeal space were collected after development of erlotinib resistance and high dose-AZD9291 treatment. The cell pellets were subsequently analyzed for S6 phosphorylation by immunofluorescence.